After working in stealth since October, Perceptive Advisors is unveiling its newest biotech: LianBio, which serves the twin mission of bringing much-needed new medicine to China and serving to U.S. biotech corporations develop their operations into Asia.
LianBio launches with a trio of property licensed from MyoKardia and BridgeBio Pharma corporations Navire Pharma and QED Therapeutics. LianBio is handing over greater than $60 million upfront in alternate for growth and commercialization rights to the packages in China and “chosen Asian markets.” BridgeBio and MyoKardia will choose up fairness within the LianBio, too.
And that’s not all—LianBio has a “strategic relationship” with BridgeBio that offers it first dibs on the 20 packages already within the latter’s pipeline, in addition to any property it could convey underneath its umbrella within the subsequent 4 years, mentioned Konstantin Poukalov, a managing director at Perceptive Advisors and govt chairman of LianBio. The corporate might be on the hook for as much as $505 million in milestone funds to BridgeBio and $147.5 million to MyoKardia.
LianBio’s pipeline contains mavacamten—a remedy for hypertrophic cardiomyopathy (HCM), an inherited dysfunction that causes the muscle partitions of the center to thicken, doubtlessly to the purpose the place they’ll obscure blood circulate. MyoKardia plans to submit the drug for FDA approval for obstructive HCM in early 2021 and proceed to develop it for sufferers with the non-obstructive type of HCM and people with a selected form of coronary heart failure, by which the left ventricle can’t correctly fill with blood and pumps much less blood to the physique than regular.
RELATED: GlaxoSmithKline veteran Zhi Hong launches Brii Biosciences with $260M
LianBio has additionally licensed infigratinib, QED Therapeutics’ EGFR inhibitor that’s in a section Three examine for bile duct most cancers, and a SHP2 inhibitor that Navire Pharma is growing for drug-resistant tumors and different hard-to-treat cancers. LianBio palms over $26.5 million upfront
The corporate views these as extra than simply licensing offers, Debra Yu, LianBio’s chief enterprise officer mentioned. It plans to pitch in and run scientific trials in China and different components of Asia the place acceptable.
“It isn’t similar to we get mavecamten and we go wherever we wish with it and pay them the royalties,” Yu mentioned.
“Within the case of mavecamten, MyoKardia already received it all over for the obstructive HCM indication and we’ll take it into China,” she added. “However for the opposite indications, in nonobstructive HCM and (coronary heart failure with preserved ejection fraction), we are going to work facet by facet with them.”
As for infigratinib, that would imply testing the drug in cancers that QED is just not but , however which can be prevalent in China, reminiscent of gastric most cancers, she added.
It’s a part of Perceptive and LianBio’s bid to convey cutting-edge medicines to China and tackle what CEO Bing Li calls the hole between world innovation and the China market.
“China has predominantly been a generics marketplace for most of its time,” Yu mentioned. “Even at the moment, there’s nonetheless a really restricted variety of revolutionary medicine and positively not these we might name ‘paradigm-shifting.”
Because it advances its pipeline, LianBio goals to double its staff by the tip of the yr. Will probably be on the hunt for extra property that it would need to pursue in China, each via its cope with BridgeBio and different potential companions.
When requested if LianBio would ever dive into in-house discovery and growth, Poukalov mentioned “nothing is ever off the desk,” however that the core focus of the corporate’s mannequin is “high-quality property which can be extremely considerably derisked.”
“However as soon as our therapeutic areas of focus are established, we’re definitely keen to maneuver to earlier phases of growth,” Poukalov added. That might embody placing collectively novel cancer-fighting mixtures primarily based on Navire’s SHP2 inhibitor.
“Within the near-term, I don’t suppose we’re going to be doing true benchwork—there are many people who find themselves good at doing that—however we might be using what we all know and the entry we’ve got to be artistic and do early-stage growth work,” he mentioned.
Editor’s word: This story has been up to date to take away the greenback quantity of LianBio’s funding because it was incorrect.